SynthesisOccupational and environmental medicine2025
Dose-response relationship of cadmium and pancreatic cancer risk: a meta-analysis.
Synthesis in Occupational and environmental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cadmium Exposure and Risk of Pancreatic Cancer: A Systematic Review and Meta-Analysis.La Medicina del lavoro · 2026Pooled it
- Trace Elements in the Pancreas: From Physiological Homeostasis to the Pathogenesis of Diabetes, Pancreatitis, and Cancer-A Review.Life (Basel, Switzerland) · 2026Review
- Genetic Polymorphisms as Modifiers of Health Risks from Exposure to Toxic Elements: A Traditional Literature Review.Toxics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cadmium (Cd), a group 1 carcinogen, is linked to the development of pancreatic cancer. Not well-defined is the dose-response relationship between Cd and cancer development.This study investigated the relationship between Cd exposure and the risk of pancreatic cancer through a meta-analysis focusing on pooled relative risk (RR), biomarker comparisons and dose-response relationships.This meta-analysis adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and applied the PECO (population, exposure, comparator and outcomes) framework. Systematic searches of key databases, including PubMed, Cochrane Library, Web of Science, EMBASE, ScienceDirect and ProQuest, were carried out without language restrictions. Studies that met the predefined PECO criteria were chosen, extracting data on effect estimates such as HRs, ORs, RRs and Cd biomarker concentrations. Analyses involved pooled RRs, standardised mean differences for biomarker comparisons and dose-response relationships, using random-effects meta-analysis and meta-regression. Statistical procedures were performed on R V.4.3.0.Cd exposure was significantly associated with an increased risk of pancreatic cancer, with a pooled RR of 1.42 (95% CI=1.16 to 1.73). Subgroup analyses confirmed this association in both occupationally and non-occupationally exposed individuals. Dose-response analyses further revealed that higher Cd biomarker levels correlated with greater pancreatic cancer risk (lnRR coefficient=0.610, p=0.035).Cd exposure is associated with an increased risk of pancreatic cancer, with a dose-response relationship and elevated biomarker levels in cases. Cd exposure is a modifiable risk factor for pancreatic cancer, meriting further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.